Bahl & Gaynor Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 77.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,012 shares of the biopharmaceutical company’s stock after selling 10,378 shares during the period. Bahl & Gaynor Inc.’s holdings in Gilead Sciences were worth $221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth $29,000. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth $29,000. Palisade Asset Management LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth $29,000. Sachetta LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Analysis on Gilead Sciences
Gilead Sciences Trading Up 2.7 %
NASDAQ GILD traded up $1.90 during trading hours on Wednesday, hitting $73.07. 2,388,029 shares of the company were exchanged, compared to its average volume of 7,406,023. The stock has a 50-day moving average price of $67.30 and a 200 day moving average price of $71.17. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a market cap of $91.03 billion, a PE ratio of 197.69, a price-to-earnings-growth ratio of 3.10 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the firm posted $1.37 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 3.72 earnings per share for the current fiscal year.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- Stock Dividend Cuts Happen Are You Ready?
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- Investing in the High PE Growth Stocks
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.